Deerfield Management Company, L.P. (Series C) Xilio Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 16, 2022	SELL	$6.63 - $16.05 $499,696 - $1.21 Million	-75,369 Reduced 3.5%	2,078,692 $14.7 Million
Q4 2021 Feb 14, 2022	BUY	$9.69 - $25.11 $20.9 Million - $54.1 Million	2,154,061 New	2,154,061 $33.7 Million

Others Institutions Holding XLO

# of Institutions

Shares Held

14M

Call Options Held

Put Options Held

Bain Capital Life Sciences Investors, LLC Boston, MA

4.57M
Shares

$4.02 Million
0.65% of portfolio
Rock Springs Capital Management LP Baltimore, MD

3M
Shares

$2.64 Million
0.08% of portfolio
Morgan Stanley New York, NY

1.52M
Shares

$1.34 Million
0.0% of portfolio
River Vest Venture Management LLC St. Louis, MO

1.44M
Shares

$1.27 Million
16.6% of portfolio
Vanguard Group Inc Valley Forge, PA

903K
Shares

$794,227
0.0% of portfolio

View Full List

About Xilio Therapeutics, Inc.

Ticker XLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,471,600
Market Cap $24.2M
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...

More about XLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account